$10.91 Million in Sales Expected for Minerva Surgical Inc (NASDAQ:UTRS) This Quarter

Equities research analysts expect Minerva Surgical Inc (NASDAQ:UTRSGet Rating) to post $10.91 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Minerva Surgical’s earnings, with the highest sales estimate coming in at $12.25 million and the lowest estimate coming in at $10.22 million. The company is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Minerva Surgical will report full-year sales of $61.21 million for the current year, with estimates ranging from $60.18 million to $61.86 million. For the next financial year, analysts forecast that the business will report sales of $81.21 million, with estimates ranging from $80.52 million to $81.62 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Minerva Surgical.

Several equities analysts have issued reports on UTRS shares. Piper Sandler dropped their price objective on Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Wednesday, March 9th. Zacks Investment Research downgraded shares of Minerva Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Minerva Surgical presently has an average rating of “Buy” and an average target price of $11.70.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Minerva Surgical in the fourth quarter valued at about $88,000. Virtu Financial LLC purchased a new position in Minerva Surgical in the fourth quarter valued at about $54,000. Millennium Management LLC bought a new position in Minerva Surgical during the 4th quarter worth approximately $134,000. Perceptive Advisors LLC bought a new position in Minerva Surgical during the 4th quarter worth approximately $451,000. Finally, Ghisallo Capital Management LLC bought a new position in Minerva Surgical during the 4th quarter worth approximately $386,000. Hedge funds and other institutional investors own 42.40% of the company’s stock.

NASDAQ:UTRS traded down $0.04 during trading hours on Friday, hitting $4.34. The company’s stock had a trading volume of 25,030 shares, compared to its average volume of 14,204. The company has a fifty day simple moving average of $4.97. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.29 and a quick ratio of 2.60. Minerva Surgical has a 52-week low of $4.16 and a 52-week high of $10.37.

About Minerva Surgical (Get Rating)

Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif.

Featured Articles

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Surgical (NASDAQ:UTRS)

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.